Breast Cancer, Version 3.2018
Matthew P. Goetz(Mayo Clinic), Rashmi Kumar(University of London), P. Kelly Marcom(Duke University), Sharon H. Giordano(The University of Texas MD Anderson Cancer Center), Mary Lou Smith(Research Advocacy Network), Lori J. Pierce(University of Michigan–Ann Arbor), Sameer A. Patel, Meena S. Moran(Cleveland Clinic), Ruth M. O'Regan(University of Wisconsin Carbone Cancer Center), Lori J. Goldstein(Shaanxi Research Association for Women and Family), Melinda L. Telli(Stanford University), Rebecca Aft(Washington University in St. Louis), Jessica Young, Harold J. Burstein(Dana-Farber Cancer Institute), Sarah L. Blair(University of California San Diego), Benjamin O. Anderson(University of Washington), Elizabeth Reed(Cancer Institute (WIA)), Chau T. Dang(Memorial Sloan Kettering Cancer Center), Ingrid A. Mayer(Vanderbilt University), Karen L. Smith(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dorothy A. Shead(University of the Witwatersrand), Amy M. Sitapati, William J. Gradishar(Northwestern University), Jame Abraham(Cleveland Clinic), Kimberly H. Allison(Stanford University), Hope S. Rugo(City of Hope), Hatem Soliman(Moffitt Cancer Center), Anthony Elias(University of Colorado Cancer Center), John H. Ward(Unknown), Janice A. Lyons, Steven J. Isakoff(Harvard University), William B. Farrar, Joanne Mortimer(City of Hope)
Cited by 199
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
|Science|2013|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k